Skip to content

Newsroom

Latest in peptide research.

Aggregated from the last 12 months across major outlets. Updated hourly. 60 articles currently in feed.

Want the highlights? Read this week’s digest.

Peptide
Eli Lilly and Company5d ago

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health - Eli Lilly and Company

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health Eli Lilly and Company

Headlines aggregated from Google News. Last 12 months. Click a headline to open the original source.

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.